Tag Archives: Innovator’s Pitch Challenge

RESI@TMCx Innovation Challenge Winners Announced

14 Apr

By Nono Hu, Director of Marketing, LSN

This week at RESI@TMCx, thirty companies from the biotech, medical device, diagnostic and healthcare IT sectors competed in the RESI Innovation Challenge. From among the applications we received, these companies were selected by LSN’s scientific review board to present their technologies in an exhibition-style format while RESI attendees cast their votes on the best innovations on display. Here are the top 3 winners!

First Prize Winner: GeneSegues Therapeutics

011

GeneSegues develops novel nanocapsule based solutions that can unlock the potential of promising drugs that need more precise delivery. Our technology is highly differentiated in that our ultra-small nanocapsule is 3x smaller than competing capsules and, due to their versatility and efficiency, can be readily designed to reach more targets with more drug leading to better treatment outcomes. We are using this technology to develop our own nanoencapsulated RNA drug for head and neck and colon cancers. In addition to developing our proprietary cancer drug candidate pipeline, we are seeking to partner our nanocapsules with drug developers in other cancer indications and other disease markets in need of innovative and effective targeted delivery solutions. We are actively engaged in a number of very high potential markets in need of new delivery technologies for RNAI, gene therapy and gene editing (also known as CRISPR). Because we can create new nanocapsules more quickly and significantly smaller than the competition, we can be a leader in some of the most exciting fields in medicine today.

01

Laura Brod, CEO, GeneSegues

Second Prize Winner: GreenLight Medical

022

GreenLight Medical is a cloud-based software to streamline the introduction, evaluation, and approval of new medical technology within hospitals. GreenLight is an end-to-end solution, offering a secure, collaborative, information-exchange platform to align medical device companies, medical sales representatives, hospital providers, and physicians in one all-inclusive tool. By eliciting coordination among multiple parties on new product evaluation, data, documents, and decisions can be analyzed from one shared space. GreenLight provides the actionable data and insights needed to enable medical suppliers and hospital providers alignment on cost, quality, and outcomes regarding new medical technology introduction.

02

Austin Dirks, CEO & CO-Founder, GreenLight Medical

Third Prize Winner: Adhesys Medical

033

Surgeons still suture or staple more than they’d like to, as medical glues don’t live up to their requirements. Adhesys Medical seeks to change the game, developing one-of-its kind polyurethane-based surgical adhesives. The technology is unique as it combines ease of use, strength, flexibility and biodegradability, allowing for wound-closure on and in the body within seconds and use in unprecedented areas of surgery. Venture backed and based in the US and Germany, it is our vision to advance surgery by providing physicians with the tools to minimize complications and maximize patient comfort.

Alexander Schüller, President & Laurence Zhu, Analyst from Adhesys with Emmanuelle Schuler Head of JLABS@TMC

Alexander Schüller, President & Laurence Zhu, Analyst from Adhesys with Emmanuelle Schuler Head of JLABS@TMC

RESI@TMCx Innovation Challenge: Participating Startups Announced

17 Mar

By Shaoyu Chang, MD, MPH, Senior Research Manager, LSN

Shaoyu 10*10

It’s time to announce the successful applicants to the RESI@TMCx Innovation Challenge. LSN’s scientific review board have assessed and ranked all entrants across a wide range of criteria, from scientific novelty to strength of IP, to select the 30 strongest entrants. These entrepreneurs will receive a presentation space in the RESI@TMCx exhibit hall for the full day of the conference to showcase their innovations to investors and fellow entrepreneurs. All RESI attendees have the opportunity to vote in the Innovation Challenge by “investing” in the best of these companies.

If your company missed this opportunity to compete in the RESI@TMCx Innovation Challenge, you can now enter the RESI on MaRS Innovation Challenge, to be held on June 23rd in Toronto.

 

RESI@JPM Innovation Challenge – Winners Announced

21 Jan

By Nono Hu, Director of Marketing, LSN

Last week, LSN’s Redefining Early Stage Investments (RESI) Conference brought together approximately 350 early stage investors and 300 biotech, medtech and healthcare IT entrepreneurs, our largest crowd to date. The RESI Innovation Challenge received a record number of applicants last fall. The 30 most innovative applicants were hand selected by Life Science Nation’s internal scientific review board and presented their technologies in an exhibition-style format throughout the full-day conference. Here are the top 3 winners!

First Prize Winner: ClearSight

01

ClearSight LLC is commercializing a novel intraocular lens (IOL), the ClearSight IOL, designed to prevent clouding of the lens known as posterior capsular opacification (PCO). PCO is the most frequent surgical complications from cataract surgery, occurring in 25% of patients and costing the U.S. healthcare system $350 million/year. Animal data demonstrates that the ClearSight IOL reduces PCO by 100% in a rabbit model, due to the patent-protected ClearSight IOL design and the addition of a novel microscopic surface texture to prevent cell migration that leads to clouding of the lens. IOLs represent a $1.1 billion U.S. market and $3.7 billion global market.

02

George Ayd, Assistant Vice President, MedMarc; Shravanthi Reddy, COO, ClearSight

 

Second Prize Winner: Eve Medical

03Eve Medical is a Toronto-based medical device company dedicated to improving women’s health. Eve’s core product HerSwab™ makes it easy for women to collect their own samples at home or in clinic to test for common infections that cause cervical cancer, pelvic inflammatory disease and infertility. This saves time, provides privacy and minimizes invasiveness. By reduce barriers to screening, and improving compliance, Eve Medical and HerSwab™ can empower under-served women, improve the reach of existing programs, increase test volumes, and reduce costs for healthcare systems.

04

Michael Quigley, VP of Market Research, LSN; Jessica Ching, CEO, Eve Medical; Dennis Ford, CEO, LSN

 

Third Prize Winner: Briteseed

05The surgeon’s lack of tactile feedback during minimally invasive laparoscopic and robotic surgery leads to difficulty in safely visualizing and manipulating blood vessels, ureters, and bile ducts. Briteseed combats this problem by building smart surgical tools using low-cost optical technology to non-invasively visualize both between and near the jaws of a surgical tool in real time. This combination hardware and software solution is flexible enough to be seamlessly integrated into a spectrum of surgical tools. These smart tools will provide imaging and diagnostic capabilities without interrupting surgical workflow, increasing user adoption. By raising the quality and decreasing overall cost of care, Briteseed provides value to surgeons and the hospital administrations that support them.

06

Michael Quigley, VP of Market Research, LSN; Mayank Vijay, Head of BD and Operations & Co-founder, Briteseed

 

RESI Innovation Challenge: Participating Startups Announced

17 Dec

By Dennis Ford, Founder & CEO, LSN

dennis-websit

The RESI Innovation Challenge received a record number of applicants this fall. LSN’s scientific review board assessed and ranked all entrants across a wide range of criteria, from scientific novelty to strength of IP, to select the 30 strongest entrants. We’d now like to announce these successful applicants. These entrepreneurs have been selected by LSN’s scientific validation team to receive a presentation space in the exhibit hall for the full day of the conference to showcase their innovations to investors and fellow entrepreneurs. We’re excited to meet all these companies in person in the Exhibitor Hall at RESI, and we hope you’ll join us there to vote for the very best of these cutting-edge life science startups.

IC Logos SF2016

Women CEOs Lead the Day at the RESI Innovation Challenge

27 Mar

By Maximilian Klietmann, VP of Marketing, LSN

Max Smile 2

RESI ended on Monday evening with over 400 attendees and over 660 partnering meetings. Additionally, 33 of the 150 biotech and medtech companies attending RESI were selected for the RESI Innovation Challenge, and competed for “RESI Cash” invested by conference attendees. Well, the winners are in:

  • The winners are global in nature, hailing from the US and Europe.
  • There was a tie for third place.
  • Women led the charge! Three of the four winning companies have women CEOs.

Scroll down to see the winning companies below (click the logos to visit company websites):

FIRST PLACE:

EMPIRIKO

Empiriko, based in Newton, MA, is addressing several of the challenges faced by scientists, clinicians and decision-makers responsible for taking drugs from concept to commercialization. The company’s Biomimiks™ solutions can help in predicting patient/drug interaction and can be used to optimize drug designs, and improve patient outcomes.

Pam Randhawa, Founder and CEO


SECOND PLACE:

BIOARRAY

BIOARRAY, based in Farmington, CT, is developing proprietary predictive diagnostic tests, based on cancer genes (markers), to choose the most efficacious treatment for cancer patients beforehand, rather than the trial and error approach currently used.

Marcia Fournier, CEO


THIRD PLACE (TIE):

STC logo

STC Biologics is a biotechnology company located in Cambridge MA focusing on development of biologic drugs. The company’s portfolio of drugs includes a MAb biosimilar for Oncology as well as a re-appropriated biologic drug for the treatment of Alzheimer’s.

Magdalena Leszczyniecka, President and CEO


THIRD PLACE (TIE):

Multineurons_logotype_300dpi

Multineurons, based in Switzerland, is developing medical devices for non-invasive and wireless brain-computer interface and brain diagnosis/therapy. The company’s products are based on a unique technology that evolved from more than a decade of R&D. 

Tasos Smeros, Founder & CEO